Methods and compositions for treatment of epileptic disorders

Inventors

During, Matthew

Assignees

Ovid Therapeutics Inc

Abstract

Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

Core Innovation

The disclosure concerns treating epileptic disorders by administering allosteric modulators of GABA-A receptors, including neurosteroids such as ganaxolone and allopregnanolone, together with other allosteric modulators such as benzodiazepines and potassium channel openers. The disclosure also provides treatment using gaboxadol (THIP) alone or in combination with allopregnanolone, ganaxolone, or lorazepam.

The disclosure frames the problem as inadequate and/or transient responses in epileptic disorders, including status epilepticus, including super-refractory status epilepticus and benzodiazepine-resistant status epilepticus. It emphasizes the need for therapies that produce improvement that lasts for more than 6 hours and potentially next-day functioning.

The disclosure also includes parenteral gaboxadol formulations and addresses solubility and stability requirements with specified formulation components such as buffers, solubilizers, tonicity agents, and EDTA. Pharmacokinetic exposure targets are described using parameters including Cmax, Tmax, and AUC0- together with in vivo plasma profiles.

Claims Coverage

The claims coverage is not explicitly described in the input items.

The input items do not provide independent claims or inventive features.

Stated Advantages

Documented Applications